Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.

Luo Y, Yang C, Lu W, Xie R, Jin C, Huang P, Wang F, McKeehan WL.

J Biol Chem. 2010 Sep 24;285(39):30069-78. doi: 10.1074/jbc.M110.148288. Epub 2010 Jul 23.

2.

Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.

Wu X, Ge H, Lemon B, Weiszmann J, Gupte J, Hawkins N, Li X, Tang J, Lindberg R, Li Y.

Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14379-84. doi: 10.1073/pnas.0907812106. Epub 2009 Aug 12.

3.

Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.

Yang C, Jin C, Li X, Wang F, McKeehan WL, Luo Y.

PLoS One. 2012;7(3):e33870. doi: 10.1371/journal.pone.0033870. Epub 2012 Mar 19.

4.

Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho.

Nakamura M, Uehara Y, Asada M, Honda E, Nagai N, Kimata K, Suzuki M, Imamura T.

J Biol Chem. 2011 Jul 29;286(30):26418-23. doi: 10.1074/jbc.M111.251140. Epub 2011 Jun 8.

5.

Co-receptor requirements for fibroblast growth factor-19 signaling.

Wu X, Ge H, Gupte J, Weiszmann J, Shimamoto G, Stevens J, Hawkins N, Lemon B, Shen W, Xu J, Veniant MM, Li YS, Lindberg R, Chen JL, Tian H, Li Y.

J Biol Chem. 2007 Oct 5;282(40):29069-72. Epub 2007 Aug 21.

6.

Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression.

Song KH, Li T, Owsley E, Strom S, Chiang JY.

Hepatology. 2009 Jan;49(1):297-305. doi: 10.1002/hep.22627.

7.

Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis.

Huang X, Yang C, Jin C, Luo Y, Wang F, McKeehan WL.

Mol Carcinog. 2009 Jun;48(6):553-62. doi: 10.1002/mc.20494.

9.

FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.

Wu AL, Coulter S, Liddle C, Wong A, Eastham-Anderson J, French DM, Peterson AS, Sonoda J.

PLoS One. 2011 Mar 18;6(3):e17868. doi: 10.1371/journal.pone.0017868.

10.

Hepatocyte FRS2α is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity.

Wang C, Yang C, Chang JY, You P, Li Y, Jin C, Luo Y, Li X, McKeehan WL, Wang F.

Curr Mol Med. 2014;14(6):703-11.

11.

FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.

Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R, Gupte J, Hager T, Wang Z, Lindberg R, Li Y.

J Biol Chem. 2010 Feb 19;285(8):5165-70. doi: 10.1074/jbc.M109.068783. Epub 2009 Dec 15.

12.

Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.

Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M.

J Biol Chem. 2007 Sep 14;282(37):26687-95. Epub 2007 Jul 10.

13.

Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.

Miura S, Mitsuhashi N, Shimizu H, Kimura F, Yoshidome H, Otsuka M, Kato A, Shida T, Okamura D, Miyazaki M.

BMC Cancer. 2012 Feb 6;12:56. doi: 10.1186/1471-2407-12-56.

14.

Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.

Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A.

J Hepatol. 2009 Jan;50(1):118-27. doi: 10.1016/j.jhep.2008.08.015. Epub 2008 Oct 12.

PMID:
19008009
15.

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.

Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N, Shutes A, Winter C, Lengauer C, Kohl NE, Guzi T.

Cancer Discov. 2015 Apr;5(4):424-37. doi: 10.1158/2159-8290.CD-14-1029. Epub 2015 Mar 16.

16.

The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.

Drafahl KA, McAndrew CW, Meyer AN, Haas M, Donoghue DJ.

PLoS One. 2010 Dec 22;5(12):e14412. doi: 10.1371/journal.pone.0014412.

17.

βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling pathway.

Ye X, Guo Y, Zhang Q, Chen W, Hua X, Liu W, Yang Y, Chen G.

PLoS One. 2013;8(1):e55615. doi: 10.1371/journal.pone.0055615. Epub 2013 Jan 30.

18.

IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes.

Zhao Y, Meng C, Wang Y, Huang H, Liu W, Zhang JF, Zhao H, Feng B, Leung PS, Xia Y.

Am J Physiol Endocrinol Metab. 2016 Feb 15;310(4):E289-300. doi: 10.1152/ajpendo.00356.2015. Epub 2015 Dec 15.

19.

Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action.

Zhang J, Gupte J, Gong Y, Weiszmann J, Zhang Y, Lee KJ, Richards WG, Li Y.

EBioMedicine. 2017 Feb;15:173-183. doi: 10.1016/j.ebiom.2016.12.016. Epub 2016 Dec 24.

20.

Different roles of N- and C- termini in the functional activity of FGF21.

Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, Dickinson CD, Kharitonenkov A.

J Cell Physiol. 2009 May;219(2):227-34. doi: 10.1002/jcp.21675.

PMID:
19117008

Supplemental Content

Support Center